Aniracetam

A nootropic compound showing cognitive improvements in Alzheimer's disease trials but not in healthy individuals.

Supplements

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Aniracetam

A nootropic compound showing cognitive improvements in Alzheimer's disease trials but not in healthy individuals.

Evidence category: Clinical study. This describes the source category, not approval or certainty.

Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.

Aniracetam is a racetam-class nootropic that has been studied in human clinical trials for cognitive impairment and dementia. In a randomized, placebo-controlled trial of 109 patients with mild to moderate Alzheimer's disease, daily aniracetam produced double-digit percentage improvements on cognitive assessment scales at 4-6 months, while placebo recipients showed deterioration over the same period. Emotional state improved significantly at 3 months in treated patients. However, efficacy in healthy individuals without cognitive impairment remains limited; animal studies in healthy mice found no cognitive enhancement. Aniracetam is approved in some countries but not the United States.

Benefits reported in the imported source

Randomized trials show cognitive and emotional improvements in Alzheimer's disease patients
Generally well-tolerated in studied populations

Risks and limits

No evidence of benefit in healthy individuals; animal studies in healthy mice showed no effect
Long-term safety beyond 12 months not established in trials
Regulatory status varies by country; not approved in United States

Source bottom line: Aniracetam has shown cognitive benefits in Alzheimer's disease trials but lacks evidence for enhancement in healthy people.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

109 patients with mild to moderate Alzheimer's disease

Reported regimen: Aniracetam oral treatment for cognitive impairment
Duration: 6 months assessment
Reported outcome: 12-35% improvement on cognitive scales vs. 9-19% deterioration in placebo; emotional state improved at 3 months
Source: Clinical Efficacy of Aniracetam, Either as Monotherapy or Combined with Cholinesterase Inhibitors, in Patients with Cognitive Impairment: A Comparative Open Study

Claim provenance

evidence.json#/catalog:supplement:aniracetam/protocols/0

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Historical research outcome: no-verified-description · 2026-10-06

No suitable community description was independently verified in these checks. The entry remains empty; this does not establish that no practice exists elsewhere.

https://nootropicsexpert.com/aniracetam/: no-practice-description — This retrieved source was checked, but no suitable community description was independently verified. Research regimens, expert advice, product identity and efficacy claims were not repurposed.

Pharmacokinetic context

No half-life recorded in this source snapshot. No value has been inferred.

Source references

Snapshot provenance

Source ID: catalog:supplement:aniracetam. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.

Related entries and components

None listed.